The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
Nightingale™ ( a patient-centered, design-forward lighting brand for healthcare environments, has unveiled its latest product ...
Visual impairment poses a growing public health challenge in the United States, with 3.22 million people affected in some way, including 1.02 million individuals experiencing blindness as of 2015.
17h
Involuntary eye movements could be targeted by restoring retinal dopamine, mouse experiments suggest
Researchers have found a possible way to stop abnormal signals in the retina that are linked to involuntary eye movements ...
Glaukos Corporation ( GKOS ), an ophthalmic pharmaceutical and medical technology company, announced positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the ...
Epioxa, an epithelium-on corneal cross-linking therapy for keratoconus, demonstrated positive outcomes in visual acuity, ...
After the liquidation of MSEC, new rules apply: we analyze the visual acuity indicators for establishing Group III disability ...
Atsena expects to complete enrollment in the third part of the Lighthouse study next year. (den-belitsky/iStock/ Plus) Atsena Therapeutics has reported evidence of efficacy in a clinical trial of an ...
ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has ...
Glaukos Corporation announced positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's ...
Three-year data demonstrate sustained improvements in corneal shape, meaningful visual acuity gains, and a favorable ...
A Syrian boy's seven-year gait disturbance was finally traced to a giant suprasellar arachnoid cyst and successfully treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results